Home > Search Results: Rubio-Terrés, Carlos
  Search Tips
Simple Search
Search collections:
Sort by: Display results: Output format:
UAB Digital Repository of Documents 2 records found  Search took 0.00 seconds. 
1.
11 p, 1.1 MB Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain / Casado, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Rosas, José (Hospital Marina Baixa (La Vila Joiosa, Alacant)) ; Rubio-Terrés, Carlos (Health Value) ; Rubio-Rodríguez, Darío (Health Value) ; Boolell, Mitra (Medical Affairs) ; Arístegui, Ignacio (Medical Affairs) ; Universitat Autònoma de Barcelona
To estimate the cost-effectiveness of treating postmenopausal osteoporosis (PMO) with weekly gastro-resistant risedronate 35 mg gastro-resistant tablets (RIS-GR), compared with weekly alendronate 70 mg tablets (ALN) in Spain. [...]
2023 - 10.57264/cer-2023-0115
Journal of Comparative Effectiveness Research, Vol. 12 (september 2023)  
Detailed record - Creative Commons
2.
9 p, 855.6 KB Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain / Grau, Santiago (Hospital del Mar (Barcelona, Catalunya)) ; Azanza Perea, José Ramón (Clínica Universidad de Navarra) ; Ruiz, Isabel (Ruiz Camps) (Hospital Universitari Vall d'Hebron) ; Vallejo, Carlos (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ; Mensa, Josep (Hospital Clínic i Provincial de Barcelona) ; Maertens, Johan (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Heinz, Werner J. (Hematology/Oncology Department, Medizinische Klinik und Poliklinik II, Universitätsklinikum, Würzburg, Germany) ; Barrueta, Jon Andoni (Medical Department) ; Peral, Carmen (Economics and Outcomes Research Department, Pfizer S.L.U, Alcobendas) ; Mesa, Francisco Jesús (Medical Department) ; Barrado, Miguel (Clinical Trials Department, Trial Form Support, Madrid, Spain) ; Charbonneau, Claudie (Pharmacoeconomics Department, Pfizer International Operations, Paris, France) ; Rubio-Rodríguez, Darío (Pharmacoeconomics Department, Health Value, Madrid, Spain) ; Rubio-Terrés, Carlos (Pharmacoeconomics Department, Health Value, Madrid, Spain) ; Universitat Autònoma de Barcelona
According to a recent randomized, double-blind clinical trial comparing the combination of voriconazole and anidulafungin (VOR+ANI) with VOR monotherapy for invasive aspergillosis (IA) in patients with hematologic disease or with hematopoietic stem cell transplant, mortality was lower after 6 weeks with VOR+ANI than with VOR monotherapy in a post hoc analysis of patients with galactomannan-based IA. [...]
2016 - 10.2147/CEOR.S122177
ClinicoEconomics and outcomes research, Vol. 9 (december 2016) , p. 39-47  
Detailed record - Creative Commons

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with